HESS-STUMP Holger
No ORCID on file
· 36 papers in corpus
· active 2001-2007
Frequent coauthors
- ZORN LUDWIG 24
- HUTH Andreas 24
- KRUEGER MARTIN 24
- MENRAD Andreas 24
- THIERAUCH Karl-Heinz 24
- HABEREY Martin 24
- INCE Stuart 24
- HAENDLER Bernard 12
- CHWALISZ Kristof 12
- LESSEY Bruce 12
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2007
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides of formula (I), the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are d…
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2005
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said …
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2004
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production a nd use thereof as medicaments for the treatment of diseases caused by persisten t angiogenesis and intermediates for production of the compounds are disclosed . Sa…
2003
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.